Terbinafine (topical)

Revision as of 19:09, 27 September 2011 by WikiBot (talk | contribs) (Protected "Terbinafine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Terbinafine (topical)
Clinical data
Pregnancy
category
  • B
Routes of
administration
Oral topical
ATC code
Pharmacokinetic data
BioavailabilityReadily absorbed
Protein binding>99%
MetabolismHepatic
Elimination half-life36 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H25N
Molar mass291.43 g/mol

WikiDoc Resources for Terbinafine (topical)

Articles

Most recent articles on Terbinafine (topical)

Most cited articles on Terbinafine (topical)

Review articles on Terbinafine (topical)

Articles on Terbinafine (topical) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Terbinafine (topical)

Images of Terbinafine (topical)

Photos of Terbinafine (topical)

Podcasts & MP3s on Terbinafine (topical)

Videos on Terbinafine (topical)

Evidence Based Medicine

Cochrane Collaboration on Terbinafine (topical)

Bandolier on Terbinafine (topical)

TRIP on Terbinafine (topical)

Clinical Trials

Ongoing Trials on Terbinafine (topical) at Clinical Trials.gov

Trial results on Terbinafine (topical)

Clinical Trials on Terbinafine (topical) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Terbinafine (topical)

NICE Guidance on Terbinafine (topical)

NHS PRODIGY Guidance

FDA on Terbinafine (topical)

CDC on Terbinafine (topical)

Books

Books on Terbinafine (topical)

News

Terbinafine (topical) in the news

Be alerted to news on Terbinafine (topical)

News trends on Terbinafine (topical)

Commentary

Blogs on Terbinafine (topical)

Definitions

Definitions of Terbinafine (topical)

Patient Resources / Community

Patient resources on Terbinafine (topical)

Discussion groups on Terbinafine (topical)

Patient Handouts on Terbinafine (topical)

Directions to Hospitals Treating Terbinafine (topical)

Risk calculators and risk factors for Terbinafine (topical)

Healthcare Provider Resources

Symptoms of Terbinafine (topical)

Causes & Risk Factors for Terbinafine (topical)

Diagnostic studies for Terbinafine (topical)

Treatment of Terbinafine (topical)

Continuing Medical Education (CME)

CME Programs on Terbinafine (topical)

International

Terbinafine (topical) en Espanol

Terbinafine (topical) en Francais

Business

Terbinafine (topical) in the Marketplace

Patents on Terbinafine (topical)

Experimental / Informatics

List of terms related to Terbinafine (topical)

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Terbinafine hydrochloride (Lamisil in UK, US, France, Canada, Romania and Hungary, also sold under the name Terbisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. As a generic it is sold under the name Zabel in Australia. It is now also available as a generic in the U.S.

Pharmacology

Terbinafine hydrochloride is a white fine crystalline powder that is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water.

Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell wall synthesis pathway.

Indications

Terbinafine is mainly effective on the dermatophytes group of fungi.

As a 1% cream or powder it is used for superficial skin infections such as jock itch (Tinea cruris), athlete's foot (Tinea pedis) and other types of ringworm.

Oral 250mg tablets are often prescribed for the treatment of onychomycosis of the toenail or fingernail due to the dermatophyte Tinea unguium. Fungal nail infections are located deep under the nail in the cuticle to which topically applied treatments are unable to penetrate in sufficient amounts. The tablets may, rarely, cause hepatotoxicity, so patients are warned of this and may be monitored with liver function tests. Alcohol consumption should also be avoided while taking terbinafine.

Specific US issues

Many health insurance companies consider these infections to be a cosmetic problem, and either do not cover the cost of the months-long course of Lamisil, which can run into the thousands of dollars, or recommend use of less expensive alternatives like fluconazole.

FDA approval

The FDA has approved the first generic versions of prescription Lamisil (terbinafine hydrochloride) tablets. The remaining patent or exclusivity for Lamisil expired on June 30, 2007.

On September 28, 2007, the U.S. Food and Drug Administration stated that Lamisil (terbinafine hydrochloride, by Novartis AG) is a new treatment approved for use by children aged 4 up. The antifungal granules that can be sprinkled on a child's food to treat ringworm of the scalp, Tinea capitis. [1]


References


nl:Terbinafine he:טרבינאפין

Template:WH Template:WikiDoc Sources Template:Jb1